FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3141054637> ?p ?o ?g. }

• W3141054637 endingPage "1311" @default.
• W3141054637 startingPage "1303" @default.
• W3141054637 abstract "Haloperidol is commonly administered in the ICU to reduce the burden of delirium and its related symptoms despite no clear evidence showing haloperidol helps to resolve delirium or improve survival. We evaluated the association between haloperidol, when used to treat incident ICU delirium and its symptoms, and mortality.Post hoc cohort analysis of a randomized, double-blind, placebo-controlled, delirium prevention trial.Fourteen Dutch ICUs between July 2013 and December 2016.One-thousand four-hundred ninety-five critically ill adults free from delirium at ICU admission having an expected ICU stay greater than or equal to 2 days.Patients received preventive haloperidol or placebo for up to 28 days until delirium occurrence, death, or ICU discharge. If delirium occurred, treatment with open-label IV haloperidol 2 mg tid (up to 5 mg tid per delirium symptoms) was administered at clinician discretion.Patients were evaluated tid for delirium and coma for 28 days. Time-varying Cox hazards models were constructed for 28-day and 90-day mortality, controlling for study-arm, delirium and coma days, age, Acute Physiology and Chronic Health Evaluation-II score, sepsis, mechanical ventilation, and ICU length of stay. Among the 1,495 patients, 542 (36%) developed delirium within 28 days (median [interquartile range] with delirium 4 d [2-7 d]). A total of 477 of 542 (88%) received treatment haloperidol (2.1 mg [1.0-3.8 mg] daily) for 6 days (3-11 d). Each milligram of treatment haloperidol administered daily was associated with decreased mortality at 28 days (hazard ratio, 0.93; 95% CI, 0.91-0.95) and 90 days (hazard ratio, 0.97; 95% CI, 0.96-0.98). Treatment haloperidol administered later in the ICU course was less protective of death. Results were stable by prevention study-arm, predelirium haloperidol exposure, and haloperidol treatment protocol adherence.Treatment of incident delirium and its symptoms with haloperidol may be associated with a dose-dependent improvement in survival. Future randomized trials need to confirm these results." @default.
• W3141054637 created "2021-04-13" @default.
• W3141054637 creator A5014524643 @default.
• W3141054637 creator A5018500786 @default.
• W3141054637 creator A5019221575 @default.
• W3141054637 creator A5025445136 @default.
• W3141054637 creator A5027038575 @default.
• W3141054637 creator A5084547266 @default.
• W3141054637 creator A5085683555 @default.
• W3141054637 creator A5091240180 @default.
• W3141054637 date "2021-04-05" @default.
• W3141054637 modified "2023-09-26" @default.
• W3141054637 title "Association Between Incident Delirium Treatment With Haloperidol and Mortality in Critically Ill Adults" @default.
• W3141054637 cites W186974930 @default.
• W3141054637 cites W2000298965 @default.
• W3141054637 cites W2004284087 @default.
• W3141054637 cites W2005674701 @default.
• W3141054637 cites W2097804942 @default.
• W3141054637 cites W2108485082 @default.
• W3141054637 cites W2113801876 @default.
• W3141054637 cites W2123098876 @default.
• W3141054637 cites W2123660700 @default.
• W3141054637 cites W2140458031 @default.
• W3141054637 cites W2157471359 @default.
• W3141054637 cites W2158210910 @default.
• W3141054637 cites W2167341915 @default.
• W3141054637 cites W2170436199 @default.
• W3141054637 cites W2334921188 @default.
• W3141054637 cites W2521541847 @default.
• W3141054637 cites W2744686933 @default.
• W3141054637 cites W2793524874 @default.
• W3141054637 cites W2803806834 @default.
• W3141054637 cites W2885896746 @default.
• W3141054637 cites W2896197442 @default.
• W3141054637 cites W2900045714 @default.
• W3141054637 cites W2950529648 @default.
• W3141054637 cites W3001629424 @default.
• W3141054637 cites W3005686380 @default.
• W3141054637 cites W3016292469 @default.
• W3141054637 cites W3022341646 @default.
• W3141054637 cites W394834127 @default.
• W3141054637 cites W4293242440 @default.
• W3141054637 doi "https://doi.org/10.1097/ccm.0000000000004976" @default.
• W3141054637 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8282692" @default.
• W3141054637 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33861548" @default.
• W3141054637 hasPublicationYear "2021" @default.
• W3141054637 type Work @default.
• W3141054637 sameAs 3141054637 @default.
• W3141054637 citedByCount "5" @default.
• W3141054637 countsByYear W31410546372022 @default.
• W3141054637 countsByYear W31410546372023 @default.
• W3141054637 crossrefType "journal-article" @default.
• W3141054637 hasAuthorship W3141054637A5014524643 @default.
• W3141054637 hasAuthorship W3141054637A5018500786 @default.
• W3141054637 hasAuthorship W3141054637A5019221575 @default.
• W3141054637 hasAuthorship W3141054637A5025445136 @default.
• W3141054637 hasAuthorship W3141054637A5027038575 @default.
• W3141054637 hasAuthorship W3141054637A5084547266 @default.
• W3141054637 hasAuthorship W3141054637A5085683555 @default.
• W3141054637 hasAuthorship W3141054637A5091240180 @default.
• W3141054637 hasBestOaLocation W31410546372 @default.
• W3141054637 hasConcept C100136789 @default.
• W3141054637 hasConcept C119060515 @default.
• W3141054637 hasConcept C120665830 @default.
• W3141054637 hasConcept C121332964 @default.
• W3141054637 hasConcept C126322002 @default.
• W3141054637 hasConcept C142724271 @default.
• W3141054637 hasConcept C17624336 @default.
• W3141054637 hasConcept C177713679 @default.
• W3141054637 hasConcept C204787440 @default.
• W3141054637 hasConcept C207103383 @default.
• W3141054637 hasConcept C27081682 @default.
• W3141054637 hasConcept C2779753318 @default.
• W3141054637 hasConcept C2780948584 @default.
• W3141054637 hasConcept C42219234 @default.
• W3141054637 hasConcept C44249647 @default.
• W3141054637 hasConcept C513476851 @default.
• W3141054637 hasConcept C71924100 @default.
• W3141054637 hasConceptScore W3141054637C100136789 @default.
• W3141054637 hasConceptScore W3141054637C119060515 @default.
• W3141054637 hasConceptScore W3141054637C120665830 @default.
• W3141054637 hasConceptScore W3141054637C121332964 @default.
• W3141054637 hasConceptScore W3141054637C126322002 @default.
• W3141054637 hasConceptScore W3141054637C142724271 @default.
• W3141054637 hasConceptScore W3141054637C17624336 @default.
• W3141054637 hasConceptScore W3141054637C177713679 @default.
• W3141054637 hasConceptScore W3141054637C204787440 @default.
• W3141054637 hasConceptScore W3141054637C207103383 @default.
• W3141054637 hasConceptScore W3141054637C27081682 @default.
• W3141054637 hasConceptScore W3141054637C2779753318 @default.
• W3141054637 hasConceptScore W3141054637C2780948584 @default.
• W3141054637 hasConceptScore W3141054637C42219234 @default.
• W3141054637 hasConceptScore W3141054637C44249647 @default.
• W3141054637 hasConceptScore W3141054637C513476851 @default.
• W3141054637 hasConceptScore W3141054637C71924100 @default.
• W3141054637 hasIssue "8" @default.
• W3141054637 hasLocation W31410546371 @default.
• W3141054637 hasLocation W31410546372 @default.

• next